RetinaCME
EXPERT VIDEOCMEABO MOC

New Treatment Options in Uveitis

Author(s)/Faculty: Lisa J. Faia, MD; Sunil K. Srivastava, MD
Release Date: 5/31/2020Expiration Date: 5/30/2021
Credit Type: CME / ABO MOCNumber of Credits: 1.25
Content Type: VideoProvider:
Noninfectious uveitis continues to be a leading cause of preventable blindness. Corticosteroid therapy is the first-line treatment of choice, but long-term administration of high-dose systemic corticosteroids is associated with elevated rates of adverse events. To address these serious adverse events, a number of corticosteroid intraocular implants and nonsteroidal therapies have been developed and are now FDA approved. Ongoing clinical studies are further defining optimal treatment protocols with these FDA approved therapies while other studies are evaluating newer therapy options such as gene therapy and biologics. In this educational activity, experts in the field examine new evidence pertaining to the safety and efficacy of corticosteroid therapy, as well as the new and emerging nonsteroidal modalities that have demonstrated improved outcomes for patients with noninfectious uveitis.